RTOG 0415: A phase III randomized study of hypofractionated 3D-CRT/IMRT versus conventionally fractionated 3D-CRT/IMRT in patients with favorable-risk prostate cancer

To determine if hypofractionated 3D-CRT/IMRT (70 Gy in 28 fractions over 5.6 weeks) will result in disease-free survival that is no worse than DFS following conventionally fractionated 3D-CRT/IMRT (73.8 Gy in 41 fractions over 8.2 weeks) in patients treated for favorable-risk prostate cancer.

You may be eligible to participate in this study if you:

• Have histologically confirmed prostate adenocarcinoma within 180 days of randomization
• Have had a history/physical examination with digital rectal examination of the prostate within 8 weeks prior to registration
• Have had a histological evaluation of prostate biopsy with assignment of  a Gleason score of 2-6 are potentially eligible for the trial
• Are in Clinical Stage T1-2c (AJCC 6th edition)

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via e-mail, please include the title of the study in your message.